France is expanding its public health reimbursement for infant bronchiolite prevention treatments, increasing coverage from 30% to 65% starting August 31, according to announcements by French health authorities. The update impacts two primary preventive options deployed to shield infants against the highly contagious respiratory syncytial virus during high-risk winter months: the monoclonal antibody treatment Beyfortus and the maternal vaccine Abrysvo.
Bronchiolitis typically triggers a breathing obstruction marked by persistent coughing and rapid, wheezing breaths in infants under two years old. While most cases remain mild, newborns and babies under two months old face a higher risk of severe complications requiring hospitalization. To combat these outcomes, health authorities established an expanded prevention strategy integrating targeted immunizations.
Beyfortus Administration and Coverage at Maternity Wards
Beyfortus is a monoclonal antibody treatment administered to newborns through a single injection to protect against the virus throughout their first high-risk season, according to health official guidelines. The injection establishes protection by the sixth day, lasting for at least five months following administration. Approved by regulators in 2022, the treatment is integrated into the annual immunization campaign, allowing medical staff to administer the injection directly inside maternity hospitals.
When administered in the maternity ward during the official campaign, the treatment is fully covered at 100% by Assurance Maladie without requiring families to pay upfront costs. For doses administered outside of this specific maternity setting, the reimbursement rate shifts from the previous 30% baseline to 65% starting August 31.
Abrysvo Maternal Vaccination and Pregnancy Coverage
Abrysvo provides an alternative preventive route through maternal immunization, having received health authority approval in 2023. Administered to pregnant women between the end of the seventh month and the close of the eighth month of pregnancy, the vaccine prompts the mother to develop antibodies that cross the placenta. This direct transfer protects the infant from birth through their first six months of life.
Pregnant women who declare their pregnancy before the end of the third month unlock full coverage for all reimbursable medical expenses starting on the first day of the sixth month of pregnancy, according to Assurance Maladie rules. This comprehensive 100% coverage applies to pharmaceutical purchases and laboratory examinations regardless of whether the costs directly relate to the pregnancy. Consequently, the Abrysvo vaccine is entirely covered without out-of-pocket expenses for eligible mothers who meet the declaration timeline.
Reimbursement Timeline and Financial Framework
The adjustment alters patient cost-sharing across both main preventative tools. Prior to the late-August transition, both Beyfortus and Abrysvo carried a standard 30% reimbursement rate through Assurance Maladie outside of specialized maternity pathways.
Pregnant women must submit their formal pregnancy declarations within the initial three-month window to ensure uninterrupted access to the 100% medical expense waiver that kicks in at the start of the sixth month, which directly facilitates no-cost acquisition of the maternal vaccine.
Related reading